JPWO2019204666A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019204666A5 JPWO2019204666A5 JP2020558508A JP2020558508A JPWO2019204666A5 JP WO2019204666 A5 JPWO2019204666 A5 JP WO2019204666A5 JP 2020558508 A JP2020558508 A JP 2020558508A JP 2020558508 A JP2020558508 A JP 2020558508A JP WO2019204666 A5 JPWO2019204666 A5 JP WO2019204666A5
- Authority
- JP
- Japan
- Prior art keywords
- lnp preparation
- preparation according
- lnp
- mol
- therapeutic protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060375A JP2024105237A (ja) | 2018-04-18 | 2024-04-03 | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659676P | 2018-04-18 | 2018-04-18 | |
| US62/659,676 | 2018-04-18 | ||
| US201962821084P | 2019-03-20 | 2019-03-20 | |
| US62/821,084 | 2019-03-20 | ||
| PCT/US2019/028207 WO2019204666A1 (en) | 2018-04-18 | 2019-04-18 | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060375A Division JP2024105237A (ja) | 2018-04-18 | 2024-04-03 | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021526505A JP2021526505A (ja) | 2021-10-07 |
| JP2021526505A5 JP2021526505A5 (https=) | 2022-05-30 |
| JPWO2019204666A5 true JPWO2019204666A5 (https=) | 2022-05-30 |
| JP7592493B2 JP7592493B2 (ja) | 2024-12-02 |
Family
ID=68239921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558508A Active JP7592493B2 (ja) | 2018-04-18 | 2019-04-18 | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
| JP2024060375A Pending JP2024105237A (ja) | 2018-04-18 | 2024-04-03 | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060375A Pending JP2024105237A (ja) | 2018-04-18 | 2024-04-03 | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11603543B2 (https=) |
| EP (1) | EP3784252A4 (https=) |
| JP (2) | JP7592493B2 (https=) |
| CN (2) | CN121775163A (https=) |
| CA (1) | CA3097411A1 (https=) |
| WO (1) | WO2019204666A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018206485B2 (en) | 2017-01-09 | 2024-12-05 | Oisin Biotechnologies | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
| WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
| SG11202105079QA (en) * | 2018-11-14 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Fusosome compositions for cns delivery |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| CN114540416A (zh) * | 2022-02-18 | 2022-05-27 | 上海交通大学 | 一种表达载体、脂质纳米粒、抗肿瘤药物及其制备方法和用途 |
| WO2024036148A1 (en) * | 2022-08-08 | 2024-02-15 | A2 Biotherapeutics, Inc. | Compositions and methods for treating blood cancers |
| CN116712406B (zh) * | 2023-04-23 | 2026-03-31 | 深圳复生命生物医药有限公司 | 一种病毒样纳米粒子核酸药物递送系统、制备方法及应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69132032T2 (de) | 1990-11-23 | 2000-12-21 | Peptech Ltd., North Ryde | Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| EP1018560A4 (en) | 1997-08-20 | 2002-10-02 | Dnavec Research Inc | CANCER TREATMENT VECTORS |
| AU1137699A (en) | 1997-11-07 | 1999-05-31 | Dalhousie University | Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor |
| US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| US6403765B1 (en) * | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
| CA2352486A1 (en) | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| CA2325088A1 (en) * | 2000-12-01 | 2002-06-01 | Fusogenix Inc. | Novel membrane fusion proteins derived from poikilothermic reovirus |
| WO2002101076A2 (en) | 2001-06-13 | 2002-12-19 | Eastern Virginia Medical School | Methods for targeted expression of therapeutic nucleic acid |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| JPWO2006043354A1 (ja) | 2004-10-20 | 2008-05-22 | 独立行政法人放射線医学総合研究所 | 組込型の低線量放射線誘導性ベクター |
| EP2167688A4 (en) | 2007-06-12 | 2010-07-28 | Univ Case Western Reserve | TARGETED CELL DEATH |
| MX2010012473A (es) | 2008-05-23 | 2011-02-23 | Siwa Corp | Metodos, composiciones y aparato para facilitar la regeneracion. |
| HUE042177T2 (hu) * | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| WO2012019053A2 (en) * | 2010-08-04 | 2012-02-09 | The Ohio State University | Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 |
| WO2012040825A1 (en) | 2010-09-29 | 2012-04-05 | Innovascreen Inc. | Recombinant polypeptides for membrane fusion and uses thereof |
| PL3586861T3 (pl) * | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| JP2014532071A (ja) * | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9750819B2 (en) * | 2012-05-23 | 2017-09-05 | Ohio State Innovation Foundation | Lipid nanoparticle compositions and methods of making and methods of using the same |
| US9687448B2 (en) * | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| WO2014153163A1 (en) | 2013-03-14 | 2014-09-25 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
| US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| KR20180118259A (ko) | 2013-03-24 | 2018-10-30 | 오이신 바이오테크놀로지스 | 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법 |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| AU2018206485B2 (en) * | 2017-01-09 | 2024-12-05 | Oisin Biotechnologies | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
| WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
| WO2020163408A2 (en) | 2019-02-04 | 2020-08-13 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins |
-
2019
- 2019-04-18 WO PCT/US2019/028207 patent/WO2019204666A1/en not_active Ceased
- 2019-04-18 US US16/388,775 patent/US11603543B2/en active Active
- 2019-04-18 CN CN202511703583.9A patent/CN121775163A/zh active Pending
- 2019-04-18 CA CA3097411A patent/CA3097411A1/en active Pending
- 2019-04-18 JP JP2020558508A patent/JP7592493B2/ja active Active
- 2019-04-18 EP EP19789049.4A patent/EP3784252A4/en active Pending
- 2019-04-18 CN CN201980041436.6A patent/CN112312918A/zh active Pending
-
2022
- 2022-11-30 US US18/060,292 patent/US20230348937A1/en not_active Abandoned
-
2024
- 2024-04-03 JP JP2024060375A patent/JP2024105237A/ja active Pending
-
2025
- 2025-01-16 US US19/025,917 patent/US20250346925A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526505A5 (https=) | ||
| JP7638973B2 (ja) | 治療薬の細胞内送達のためのカーボネート含有脂質化合物及び組成物 | |
| ES2968649T3 (es) | Nanopartículas lipídicas para la administración de ARNm en los pulmones | |
| ES2993135T3 (en) | Codon-optimized mrna encoding cftr for use in treating cystic fibrosis | |
| JP2026050449A (ja) | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 | |
| US20220370624A1 (en) | Lipid compositions comprising peptide-lipid conjugates | |
| IL302770A (en) | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines | |
| US20250136953A1 (en) | Compositions and methods for the treatment of ornithine transcarbamylase deficiency | |
| JP2025502627A (ja) | 治療剤の送達のための化合物及び組成物 | |
| CN112533909A (zh) | 维生素阳离子脂质 | |
| JPH06510036A (ja) | 嚢胞性線維症の治療のための組成物および方法 | |
| CN113710799A (zh) | 用于在LNP中使用的编码CAS9的优化mRNA | |
| US12370238B2 (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
| CA2214029A1 (en) | Single-vial formulations of dna/lipid complexes | |
| JP2000516209A (ja) | カチオン性両親媒性物質／ｄｎａ複合体 | |
| US20150297749A1 (en) | Low-density lipoprotein analogue nanoparticles, and composition comprising same for targeted diagnosis and treatment of liver | |
| WO2024109929A1 (zh) | 可离子化脂质及其应用 | |
| US20220378702A1 (en) | Peptide-lipid conjugates | |
| JPWO2019204666A5 (https=) | ||
| WO2025189685A1 (zh) | 一种嵌合抗原受体纳米复合物及其制备方法和在制备抗衰老药物中的应用 | |
| CN113403313B (zh) | 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用 | |
| KR20220117133A (ko) | 양이온성 분자 수송체 및 SARS-CoV-2 mRNA의 이온 복합체를 포함하는 코로나바이러스감염증-19 예방 백신 조성물 | |
| WO2025180418A1 (zh) | 用于pcsk9基因修饰或编辑的组合物及其使用方法 | |
| WO2025082397A1 (zh) | 用于递送的脂质化合物及脂质纳米颗粒 | |
| CN116963770B9 (zh) | 疫苗组合物和疫苗组合物的制备方法 |